600511 国药股份
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入13,555,3206.63%52,468,28150,597,45049,696,04645,498,584
减:营业总成本13,016,1306.74%50,383,12948,403,88747,194,08943,218,513
    其中:营业成本12,728,5946.87%49,008,44347,002,22645,704,77641,676,318
               财务费用(2,876)-59.27%(21,877)(68,030)(126,127)(28,840)
               资产减值损失(3,855)-34.40%(5,564)(1,066)389(5,140)
公允价值变动收益----66(18,202)10,817--
投资收益128,89911.09%566,777514,166358,952291,622
    其中:对联营企业和合营企业的投资收益112,2388.86%546,994515,180456,539380,800
营业利润606,5910.99%2,621,6642,677,4222,944,3582,694,923
利润总额606,7810.15%2,600,1432,653,6122,930,8902,687,886
减:所得税费用115,266-4.59%510,739523,832596,420559,181
净利润491,5151.33%2,089,4042,129,7812,334,4712,128,705
减:非控股权益17,251-33.77%92,810129,654188,472164,648
股东净利润474,2643.32%1,996,5932,000,1272,145,9991,964,058

市场价值指针
每股收益 (元) *0.6293.32%2.6462.6512.8442.603
每股派息 (元) *----0.8000.8000.8540.782
每股净资产 (元) *25.2438.30%24.57922.70120.90918.840
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容